PE20061427A1 - Metodos para identificar objetivos terapeuticos para el tratamiento de la atrofia vulvovaginal - Google Patents

Metodos para identificar objetivos terapeuticos para el tratamiento de la atrofia vulvovaginal

Info

Publication number
PE20061427A1
PE20061427A1 PE2006000287A PE2006000287A PE20061427A1 PE 20061427 A1 PE20061427 A1 PE 20061427A1 PE 2006000287 A PE2006000287 A PE 2006000287A PE 2006000287 A PE2006000287 A PE 2006000287A PE 20061427 A1 PE20061427 A1 PE 20061427A1
Authority
PE
Peru
Prior art keywords
molecula
peptide
seq
acid
diethylpyridine
Prior art date
Application number
PE2006000287A
Other languages
English (en)
Inventor
Judy Sue Crabtree
Heather Anne Harris
Xiaochun Zhang
Bryan John Peano
Scott Alan Jelinsky
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20061427A1 publication Critical patent/PE20061427A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Abstract

SE REFIERE A UN COMPUESTO TERAPEUTICO QUE COMPRENDE UNA MOLECULA EFECTORA QUE MODULA LA ACTIVIDAD DE LOS RECEPTORES DE HIF 1a (FACTOR 1 ALFA INDUCIBLE POR HIPOXIA) O BETACELULINA, INCREMENTANDO LA ACTIVIDAD DE HIF 1a, DONDE LA MOLECULA EFECTORA ES SELECCIONADA DE DIFENILALCANOS (TAL COMO DIMBENZOILMETANO) O ACIDOS CARBAMOIL-FENOXIACETICOS SUSTITUIDOS CON O (TAL COMO MERSALIL), ESTER ALQUILICO DE ACIDO OXALAMICO (TAL COMO DIMETILOXALIL GLICINA), PIRIDINAS DISUSTITUIDAS (DIETILPIRIDINA DICARBOXILATO); HETEROARILO QUE CONTIENE N DE FORMULA (I) (WO2004/4108681), SIENDO SELECCIONADOS: ACIDO {(7-CLORO-3-HIDROXI-QUINOLINA-2-CARBONIL)-AMINO]-ACETICO, ACIDO 4-OXO-1,4-DIHIDRO-[1,10]FENATROLINA-3-CARBOXILICO, ENTRE OTROS; UN siARN QUE TENGA COMO OBJETIVO UN PHD O FIH; UN PEPTIDO NODDD QUE COMPRENDE LA SEC ID NO:2; UN PEPTIDO CODDD QUE COMPRENDE LA SEC ID NO:3; UNA PROTEINA DE BETACELULINA O DERIVADOS O UN PEPTIDO DE BETACELULINA QUE COMPRENDE LA SEC ID NO:1; ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO PARA IDENTIFICAR MOLECULAS OBJETIVO PARA LA TERAPIA DE ATROFIA VULVOVAGINAL MEDIANTE TAMIZADO GENETICO
PE2006000287A 2005-03-17 2006-03-15 Metodos para identificar objetivos terapeuticos para el tratamiento de la atrofia vulvovaginal PE20061427A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66266305P 2005-03-17 2005-03-17
US68894605P 2005-06-09 2005-06-09

Publications (1)

Publication Number Publication Date
PE20061427A1 true PE20061427A1 (es) 2007-01-11

Family

ID=36741332

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000287A PE20061427A1 (es) 2005-03-17 2006-03-15 Metodos para identificar objetivos terapeuticos para el tratamiento de la atrofia vulvovaginal

Country Status (6)

Country Link
US (1) US20060216295A1 (es)
AR (1) AR055319A1 (es)
GT (1) GT200600115A (es)
PE (1) PE20061427A1 (es)
TW (1) TW200716224A (es)
WO (1) WO2006099610A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515966A (ja) * 2003-12-23 2007-06-21 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 疾患の併用療法のための組成物および方法
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
EP1983823A1 (en) * 2006-01-17 2008-10-29 VIB vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
EP2041072B1 (en) 2006-06-28 2013-09-11 Sanofi Cxcr2 antagonists
EP2040688B1 (en) 2006-06-28 2014-04-02 Sanofi New cxcr2 inhibitors
JP5232144B2 (ja) 2006-06-28 2013-07-10 サノフイ Ｃｘｃｒ２阻害剤
WO2008000410A1 (en) 2006-06-30 2008-01-03 Sanofi-Aventis Cxcr2 inhibitors
AU2007334323B2 (en) * 2006-12-18 2011-03-10 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CA2672652C (en) * 2006-12-18 2012-04-17 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2142509B1 (en) * 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
AU2008241577B2 (en) * 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
EP2155746A2 (en) * 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity
AU2008248234B2 (en) * 2007-05-04 2011-02-03 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
FR2956392A1 (fr) 2010-02-15 2011-08-19 Sidel Participations Dispositif de transfert d'objet et pince correspondante
HUE031658T2 (en) 2011-02-07 2017-07-28 Biogen Ma Inc S1P modulating agents
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
CN1602360A (zh) * 2001-12-06 2005-03-30 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
JP2006527200A (ja) * 2003-06-06 2006-11-30 ファイブロゲン インコーポレイティッド 窒素含有ヘテロアリール化合物および内因性エリトロポエチンを増加させる際のそれらの使用方法

Also Published As

Publication number Publication date
AR055319A1 (es) 2007-08-15
TW200716224A (en) 2007-05-01
WO2006099610A2 (en) 2006-09-21
GT200600115A (es) 2006-11-29
WO2006099610A3 (en) 2007-09-13
US20060216295A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
PE20061427A1 (es) Metodos para identificar objetivos terapeuticos para el tratamiento de la atrofia vulvovaginal
Le Trionnaire et al. The synthesis and functional evaluation of a mitochondria-targeted hydrogen sulfide donor,(10-oxo-10-(4-(3-thioxo-3 H-1, 2-dithiol-5-yl) phenoxy) decyl) triphenylphosphonium bromide (AP39)
CY1113177T1 (el) Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
EA201070572A1 (ru) Модуляция транспорта белков
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
CY1112115T1 (el) Παραγωγα φαινοξυοξικου οξεος χρησιμα για τη θεραπευτικη αντιμετωπιση ασθενειων του αναπνευστικου
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
EA200401398A1 (ru) Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы
EA200700556A1 (ru) Замещенные бензоилом серин-амиды
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
EA200300942A1 (ru) Производные n-(арилсульфонил)бета-аминокислот, содержащие замещенную аминометильную группу, способ их получения и содержащие их фармацевтические композиции
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EP2588491A4 (en) NEW PEPTIDE AND ITS USE
BRPI0509982A8 (pt) cepa isolada de escherichia coli, e, método para produzir um composto
CY1112185T1 (el) Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
EA201270410A1 (ru) Производное инденона и содержащая его фармацевтическая композиция
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
ECSP10010321A (es) Bisfosfonatos de alquilo de 2 a 5 átomos de carbono-imidazol
MX2014015876A (es) Peptidos de penetracion celular con eif4e como objetivo.
CO5640064A2 (es) Citomodilacion de peptidos para tratar cistitis intersticial
ECSP24003395A (es) Sal

Legal Events

Date Code Title Description
FA Abandonment or withdrawal